Indeed, targeting ribosome biogenesis and protein translation by combining CX-5461 with the mTORC1 inhibitor, everolimus, synergistically reduced tumour burden and provided remarkable improvement in survival rate of MYC-driven lymphoma-bearing mice [105]. Here, MYC is linked to neoplasm.